Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 6/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641772 | 0.82 | L3MBTL1 (0.43) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL388129 | 0.82 | L3MBTL1 (0.43) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL1626536 | 0.80 | L3MBTL1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL2650212 | 0.80 | L3MBTL1 (0.46) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL3941116 | 0.80 | L3MBTL1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL4636620 | 0.80 | MCL1 (0.48) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL9202305 | 0.78 | NMT1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL13677614 | 0.78 | HTR6 (0.44) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| Fluoride SCHEMBL27733765 | 0.78 | L3MBTL1 (0.45) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| Hydrochloric Acid SCHEMBL27293487 | 0.78 | L3MBTL1 (0.45) | L3MBTL1FPR2PROKR1MCL1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | claimed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | L3MBTL1 3888/4885FPR2 65/4885PROKR1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.